




### Overall survival-FFPE



### Overall survival-FF



### Disease free survival-FFPE



**Supplementary Fig. S1.** Forest plot for the subgroup analysis between *Fusarium nucleatum* and survival in colorectal cancer [1-8]. (A) Overall survival with formalin-fixed paraffin-embedded (FFPE) tissues. (B) Overall survival with fresh frozen (FF) tissues. (C) Disease-free survival with FFPE tissues. HR, hazard ratio; CI, confidence interval.

### References

1. Sakamoto Y, Mima K, Daitoku N, et al. *Fusobacterium nucleatum* in colorectal cancer liver metastasis and patient prognosis. *Cancer Sci* 2018; 109: 1360.
2. Chen Y, Lu Y, Ke Y, Li Y. Prognostic impact of the *Fusobacterium nucleatum* status in colorectal cancers. *Medicine (Baltimore)* 2019; 98: e17221.
3. Wei Z, Cao S, Liu S, et al. Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism. *Oncotarget* 2016; 7: 46158-72.
4. Yamaoka Y, Suehiro Y, Hashimoto S, et al. *Fusobacterium nucleatum* as a prognostic marker of colorectal cancer in a Japanese population. *J Gastroenterol* 2018; 53: 517-24.
5. Sun Y, An QM, Tian XY, et al. *Fusobacterium nucleatum* infection is correlated with tumor metastasis and postoperative survival of colorectal cancer patients in China. *Transl Cancer Res* 2016; 5: 579-88.
6. Kunzmann AT, Proenca MA, Jordao HW, et al. *Fusobacterium nucleatum* tumor DNA levels are associated with survival in colorectal cancer patients. *Eur J Clin Microbiol Infect Dis* 2019; 38: 1891-9.
7. Yan X, Liu L, Li H, Qin H, Sun Z. Clinical significance of *Fusobacterium nucleatum*, epithelial-mesenchymal transition, and cancer stem cell markers in stage III/IV colorectal cancer patients. *Onco Targets Ther* 2017; 10: 5031-46.
8. Oh HJ, Kim JH, Bae JM, Kim HJ, Cho NY, Kang GH. Prognostic impact of *Fusobacterium nucleatum* depends on combined tumor location and microsatellite instability status in stage II/III colorectal cancers treated with adjuvant chemotherapy. *J Pathol Transl Med* 2019; 53: 40-9.